HOME >> MEDICINE >> NEWS
CellCept associated with reduced incidence of cancer, compared to AZA, following heart transplant

San Francisco, April 23, 2004 - A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCept (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens. Presented at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT), the study found a 27% lower risk of cancer in CellCept-treated patients. Patients studied were part of the ISHLT Transplant Registry. "Though not derived from randomized controlled trials, these data indicate that the choice of maintenance immunosuppressive regimen may be a modifiable risk factor for the development of malignancy in heart transplant recipients," said James O'Neill, M.D., Fellow in Heart Failure and Cardiac Transplantation, Cleveland Clinic.

Previous research had shown that organ transplant recipients receiving immunosuppressive therapy are three to four times more likely to develop tumors than the general population and have an even greater risk of developing certain rare cancers.

Extensive Examination of Registry Validates CellCept Treatment
The study, Mycophenolate Mofetil and the Risk of Developing Malignancy Following Orthotopic Heart Transplantation (OHT), examined competing risk factors to determine which are associated with malignancy following OHT, and was based on 3,895 patients in the ISHLT Transplant Registry. The study examined survival without malignancy in patients taking standard immunosuppressive regimens (defined as cyclosporine or tacrolimus and azathioprine or CellCept), who underwent OHT between January 1, 1995, and December 31, 1997.

Of these patients, 703 (18%) developed malignancy during the follow-up period through June 30, 2002. The breakdown of malignancy was as follows: skin (47%), post-transplant lymphoproliferative disease (10%),
'"/>

Contact: Julip Cantre
Julio.Cantre@ketchum.com
917-204-0599
Ketchum
23-Apr-2004


Page: 1 2 3

Related medicine news :

1. New data supports CellCepts position as a world leader in solid organ transplantation
2. CellCept(R) registry data demonstrated superior long-term organ transplant outcomes
3. CellCepts cardioprotective profile reinforced
4. Data shows life of kidney transplant lengthened by CellCept
5. Organizational traits associated with quality patient care are essential to home care nursing
6. Depression may explain higher risk of heart attack associated with antidepressants
7. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
8. Inpatient smoking cessation counseling is associated with early differences in mortality
9. Hypothyroidism associated with reduced breast cancer risk
10. COX-2 inhibitors associated with blood pressure elevation
11. Mothers depression associated with increased risk of childs antisocial behavior

Post Your Comments:
(Date:10/31/2014)... 2014 The Memory Healer review published by ... Lynch, whose father suffered from Alzheimer's disease. , In ... by his father's disease. His father pointed a gun and ... moment when the author of this method understood that he ... The Memory Healer program is based on years of research. ...
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... City, UT (PRWEB) October 31, 2014 ... the new Activz Silver line offering natural ... cleansing wipes. For over a century, silver has been ... found in Activz Silver products is the most advanced ... patents, has a unique chemical structure that supports the ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... – New research suggests that insomnia is a major ... other unintentional fatal injuries. The results underscore the importance ... National Healthy Sleep Awareness Project. , Results show that ... dose-dependent manner with the number of insomnia symptoms present. ... times more likely to die from a fatal injury ...
Breaking Medicine News(10 mins):Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
(Date:10/31/2014)... Imago BioSciences, Inc., a biotech company ... Series A financing led by Clarus Ventures LLC, ... of accomplished investment and operating professionals dedicated to ... include Frazier Healthcare, Amgen Ventures, and Merck Research ... Frazier Healthcare will join the company,s board of ...
(Date:10/31/2014)... 2014  Lycera Corp., a biopharmaceutical company developing ... and cancer, today announced that data on the ... candidates will be presented at the annual meeting ... being held November 6-9, 2014 at the Gaylord ...  The poster, entitled " Novel synthetic RORgamma agonist ...
(Date:10/31/2014)... LONDON , October 31, 2014 ... Nanosphere Inc. (NASDAQ: NSPH ), Isis Pharmaceuticals ... (NASDAQ: HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... SNTA). Free research on these five companies can be ... October 30, 2014, the NASDAQ Composite ended at 4,566.14, ...
Breaking Medicine Technology:Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
Cached News: